The Patent Finder

Pyrimidine Compound as Jak Kinase Inhibitor

Theravance, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 7 of these applications claim priority to application 62/577,852, filed Oct 27, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,308,646Pyrimidine Compound as Jak Kinase Inhibitor
In force
 · High confidence
Theravance Biopharma R&D IP, LLCIn force
High confidence
US 10,562,894Pyrimidine Compound as Jak Kinase Inhibitor
In force
 · High confidence
Theravance Biopharma R&D IP, LLCIn force
High confidence
US 10,774,080Pyrimidine Compound as Jak Kinase Inhibitor
In force
 · High confidence
Theravance Biopharma R&D IP, LLCIn force
High confidence
US 10,988,470Pyrimidine Compound as Jak Kinase Inhibitor
In force
 · High confidence
Theravance Biopharma R&D IP, LLCIn force
High confidence
US 11,420,965Pyrimidine Compound as Jak Kinase Inhibitor
In force
 · High confidence
Theravance Biopharma R&D IP, LLCIn force
High confidence
US 11,814,377Pyrimidine Compound as Jak Kinase Inhibitor
In force
 · High confidence
Theravance Biopharma R&D IP, LLCIn force
High confidence
US 12,172,994Pyrimidine Compound as Jak Kinase Inhibitor
In force
 · Medium confidence
Theravance Biopharma R&D IP, LLCIn force
Medium confidence
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited